Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

As for March 26, 2020



1.BCG Vaccine Clinical Experiment for Against Covid-19

Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.

Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.

The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.



2.Introduce of VPM1002，a Genetically Modified More Effective BCG Vaccine

VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.

The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.

Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.



3.Research Progress for VPM1002

Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.

The vaccine is currently being tested in a further Phase III study on adult volunteers in India.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry chain, the market status of 0-5 Years Old (0.5ml Package, 1ml Package), 5-18 Years Old (0.5ml Package, 1ml Package), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.

Regionally, the report analyzes the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Doses), revenue generated, and market share of different by Type (e.g., 0.5ml Package, 1ml Package).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.

Regional Analysis: The report involves examining the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19:

Company Analysis: Report covers individual VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (0-5 Years Old, 5-18 Years Old).

Technology Analysis: Report covers specific technologies relevant to VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19. It assesses the current state, advancements, and potential future developments in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination

Market segment by Application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old

Major players covered
Vakzine Projekt Management (VPM)
Serum Institute of India

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, with price, sales, revenue and global market share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 from 2019 to 2024.

Chapter 3, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.

Chapter 14 and 15, to describe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 sales channel, distributors, customers, research findings and conclusion.